Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro, David M O'Malley, Ana Oaknin, Premal Thaker, Amit M Oza, Nicoletta Colombo, David Gershenson, Carol A Aghajanian, Chel Hun Choi, Yeh Chen Lee, Mansoor Raza Mirza, Robert L Coleman, Lauren Cobb, Philipp Harter, Stephanie Lustgarten, Hagop Youssoufian, Susana Banerjee
BACKGROUND: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with defactinib has demonstrated efficacy and a consistent safety profile in two clinical trials in recurrent low grade serous ovarian cancer, and a lower discontinuation rate due to adverse events compared with historical rates for standard of care. PRIMARY OBJECTIVE: To compare the progression free survival of the combination of avutometinib with defactinib versus investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer...
October 7, 2024: International Journal of Gynecological Cancer